PR Newswire
AUSTIN, Texas, July 19, 2016
AUSTIN, Texas, July 19, 2016 /PRNewswire/ -- ASPiRA LABS, a Vermillion company (NASDAQ: VRML), today announced an agreement with Priority Health Managed Benefits, a Michigan healthcare insurance company, for coverage of ASPiRA LABS' ovarian cancer risk assessment test, OVA1.
"We are pleased to announce OVA1 payer coverage with Priority Health," said Valerie Palmieri, President and CEO of Vermillion, Inc. "A positive ovarian cancer outcome starts with early detection and the right treatment, at the right time, for the right patient, and results in improved healthcare efficiencies. The mortality rate of ovarian cancer has not changed in 40 years, even following the introduction of CA125. Expanding access to OVA1 is key to our fundamental mission to serve women at an elevated risk for ovarian cancer. This contract is part of our campaign to pursue managed care coverage agreements throughout 2016. We hope to expand OVA1 test adoption, further build our data repository and expansion of our clinical studies to demonstrate the 'total cost of care' benefit of OVA1 to healthcare systems."
Visit our website for more information about our products at http://www.aspiralab.com and http://www.knowpelvicmass.com.
About Vermillion
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women conquer serious diseases. The company's initial in vitro diagnostic test, OVA1®, was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016 Vermillion received FDA clearance for Overa™, a second generation OVA1 test with significantly improved specificity and ease of use. For additional information, including published clinical trials, visit www.vermillion.com.
About OVA1® and Overa™
Investor Relations Contact:
Michael Wood
LifeSci Advisors LLC
Tel 1-646-597-6983
[email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aspira-labs-announces-strategic-michigan-coverage-for-ova1-300300632.html
SOURCE Vermillion, Inc.
We use cookies to tailor your experience, measure site performance and present relevant offers and advertisements. By clicking ‘Accept’ or any content on this site, you agree that cookies can be placed on your browser. You can view our privacy policy to learn more.
If you would like to get more data, alerts and access to Real Vision videos, join us as an Insider Tracking Advantage Ultra member